Evidence map›Paper›PMID 39364267›Full record

ReviewBioMed research international2024

Review on Recent Advance of 3DP-Based Pediatric Drug Formulations.

Aychew Mekuriaw Tegegne, Kassahun Dires Ayenew, Muluken Nigatu Selam

Abstract readReview
In one paragraph

Review in BioMed research international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aychew Mekuriaw TegegneDepartment of Pharmacy Medicine and Health Science College Debre Berhan University, Debre Berhan, Ethiopia.ORCID https://orcid.org/0009-0007-6909-3320
Kassahun Dires AyenewDepartment of Pharmacy Medicine and Health Science College Debre Berhan University, Debre Berhan, Ethiopia.ORCID https://orcid.org/0000-0002-3213-0681
Muluken Nigatu SelamDepartment of Pharmaceutics and Social Pharmacy School of Pharmacy College of Health Sciences Addis Ababa University, Addis Ababa, Ethiopia.ORCID https://orcid.org/0000-0002-3539-536X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Three-dimensional printing (3DP) has emerged as a game-changing technology in the pharmaceutical industry, providing novel formulation development in the pharmaceutical sector as a whole, which improved patients' individualized therapy. The pediatric population is among the key targets for individualized therapy. Children are a diverse group that includes neonates, infants, and toddlers, each with unique physiological characteristics. Treatment adherence has a significant impact on safe and effective pharmacotherapy in the pediatric population. Improvement of therapeutic dosage forms that provide for the special demands of the pediatric population is a significant challenge for the pharmaceutical industry. Scientists have actively explored 3DP, a quick prototype manufacturing method that has emerged in recent years from many occupations due to its benefits of modest operation, excellent reproducibility, and vast adaptability. This review illuminates the most widely used 3DP technology and its application in the development of pediatric-friendly drug formulations. This 3DP technology allows optimization of pediatric dosage regimens and cases that require individualized treatment, such as geriatrics, renal impairment, liver impairment, critically ill, pregnancy populations, and drugs with nonlinear pharmacokinetics. The fast evolution of 3DP expertise, in addition to the introduction of pharmaceutical inks, has enormous promise for patient dosage form customization.

Indexed as

Printing, Three-DimensionalChildChild, PreschoolDrug CompoundingHumansInfantInfant, NewbornPediatricsPharmaceutical PreparationsPharmaceutical Preparations3DP technologydosage formindividualized therapypediatric formulation

Identifiers

PMID39364267
PMCPMC11449557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.